CV chronicles

CV chronicles

CV chroniclesWith its shares down 62% since it launched angina drug Ranexa ranolazine in March 2006, CV Therapeutics last week asked biotech banker Fred Frank of Lehman to counsel the company on strategic alternatives. A big chunk of the valuation falloff came on March 6,

Read the full 468 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE